Showing 1101-1110 of 1867 results for "".
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Sun Pharma to Acquire Concert Pharmaceuticals, Maker of Alopecia Areata Treatment Candidatehttps://practicaldermatology.com/news/sun-pharma-to-acquire-concert-pharmaceuticals-maker-of-alopecia-areata-treatment-candidate/2461519/Sun Pharmaceutical Industries announced it has acquired Concert Pharmaceuticals for about $576 million in equity value, according to a company news release. Concert’s lead product candidate is deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia a
- University of Missouri-Columbia-Developed Teledermatology Program Improves Diagnosis of Skin Conditions in Underserved Communitieshttps://practicaldermatology.com/news/university-of-missouri-columbia-developed-teledermatology-program-improves-diagnosis-of-skin-conditions-in-underserved-communities/2461517/A teledermatology program first developed by the University of Missouri in 2015 can help improve the diagnoses of skin conditions in underserved communities, according to a new study in Journal of Telemedicine
- Hydrafacial Improves Acne Skin Concerns: Studyhttps://practicaldermatology.com/news/hydrafacial-improves-acne-skin-concerns-study/2461501/Hydrafacial improves acne skin concerns, according to a new study published in the Journal of Clinical and Aesthetic Dermatology (JCAD). Fully 100 percent of study participants reported clearer, less inflamed skin after a series of treatments with Hydrafacial’s pate
- AAD Issues Updated Guidelines for the Management of Atopic Dermatitis in Adults with Topical Therapieshttps://practicaldermatology.com/news/aad-issues-updated-guidelines-for-the-management-of-atopic-dermatitis-in-adults-with-topical-therapies/2461499/The American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, re
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’
- Study: Isolated Nail PsO Not Linked to Metabolic Syndrome Riskhttps://practicaldermatology.com/news/study-isolated-nail-psoriasis-not-linked-to-metabolic-syndrome-risk/2461456/Isolated nail psoriasis does not increase risk for metabolic syndrome, according to a letter to the editor in the Journal of the European Academy of Dermatology & Venereology. The analysis include
- Almirall Appoints Mercedes Diz as VP, Corporate Strategyhttps://practicaldermatology.com/news/almirall-appoints-mercedes-diz-as-vp-corporate-strategy/2461449/Almirall named Mercedes Diz as its VP Corporate Strategy. Diz will also join Almirall's Management Board of Directors, effective December 1. Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Str
- Meta-analysis: Early Use of Emollients Can Help Preventing AD in High-risk Infantshttps://practicaldermatology.com/news/meta-analysis-early-use-of-emollients-can-help-preventing-ad-in-high-risk-infants/2461445/Early application of emollients is an effective strategy for preventing atopic dermatitis (AD) in high-risk infants, according to a meta-analysis in the Journal of the European Academy of Dermatology &am